Study of a DNA Immunotherapy to Treat Melanoma

• ClinicalTrials.gov Identifier: NCT01138410
• Recruitment Status: Terminated
• First Posted: June 7, 2010
• Last Update Posted: August 21, 2017
• Sponsor: Scancell Ltd
• Information provided by (Responsible Party): Scancell Ltd

Study Description

Brief Summary:

The study is an investigation of a novel immunotherapy, SCIB1, for the treatment of melanoma. SCIB1 is a solution of plasmid DNA molecules which will express a modified antibody in human cells. The antibody modifications are designed to stimulate the patient's immune T cells to have a strong and specific reaction against melanoma cells which should then be eliminated. SCIB1 is injected into muscle using a device which simultaneously delivers an electrical impulse to enhance the transfer of SCIB1 into muscle cells. The trial will assess the safety and tolerability of SCIB1, the safety and performance of the injection device and the immunological effects of SCIB1. This is the first study of SCIB1 in humans and the trial has two parts, in the first part the dose will be escalated to determine a safe and tolerable level up to a maximum of 8 mg per dose. In the second part patients will receive the dose determined in the first part. Patients will have stage III or IV melanoma, be HLA type A2 and have a life expectancy of at least three months. All patients will receive 5 injections of SCIB1 over 5.5 months. At the discretion of the investigator, patients may continue to receive SCIB1 at 3-6 month intervals for 5 years. The study will be conducted at major cancer centres in the UK only and is expected to last for seven years. Patients will be followed up for five years after they have completed the trial.

Condition or disease	Intervention/treatment	Phase
Malignant Melanoma	Biological: SCIB1	Phase 1; Phase 2

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 35 participants
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: A Phase I/II Trial of SCIB1, a DNA Immunotherapy, in the Treatment of Patients With Malignant Melanoma
• Actual Study Start Date: May 2010
• Actual Primary Completion Date: July 7, 2017
• Actual Study Completion Date: July 7, 2017

Arms and Interventions

Arm

Intervention/treatment

Experimental: SCIB1

Biological: SCIB1; Aqueous solution of plasmid DNA administered by intramuscular injection using the TDS-IM electroporation device (Ichor Medical Systems, Inc.) at week 0, 3, 6, 12 and 24. Part 1 of the study will escalate through 0.4, 2.0, 4.0 and 8.0 mg dose level cohorts, each of three patients. In Part 2 of the study the 4.0 and 8.0 mg doses will be administered in the same regimen. At the discretion of the investigator, patients in both parts of the study may continue to receive SCIB1 at 3-6 month intervals for 5 years.

Outcome Measures

Primary Outcome Measures :

1. Safety & Tolerability [ Time Frame: Duration of treatment phase: up to 5.5 years ]
   Recording and assessment of adverse events to establish safety and tolerability of an investigational immunotherapy, SCIB1, in patients with melanoma whose cancer has spread from the initial tumour (i.e., stage III or stage IV melanoma).

Secondary Outcome Measures :

1. Safety, tolerability, biological and clinical effects [ Time Frame: Duration of treatment phase: up to 5.5 years ]

   (i) Recording and assessment of adverse events and patient recorded experience to establish safety and tolerability of SCIB1 administered intramuscularly to melanoma patients using the TDS IM device.

   (ii) Cellular immune response by ex vivo assay induced by SCIB1 administered intramuscularly to melanoma patients using the TDS-IM device.

   (iii) Tumour response by CT scan in patients treated with SCIB1 (Part One only).

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

Part One and Part Two (8.0 mg dose):

• Histologically confirmed Stage IV or Stage III malignant melanoma, as defined by the American Joint Committee on Cancer (AJCC).
• Must have measurable disease (RECIST 1.0)

Part Two (4.0 mg dose) only:

• Histologically confirmed, resected Stage III or resected Stage IV malignant melanoma, as defined by the AJCC, within 12 months of resection and with no tumour detectable at the time of screening.

Part One and Part Two:

• HLA-A2 positive.
• Positive for HLA-DR4, HLA-DR7, HLA-DR53 or HLA-DQ6.
• Lymphocyte count ≥ 5 x 10e9 cells/mL.
• Serum lactate dehydrogenase (LDH) ≤ upper limit of normal.
• Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2.
• Willing and able to give written, informed consent.
• If male or female of childbearing potential, must be willing to use an effective contraceptive during the course of the study and for three months afterwards.

Exclusion Criteria:

• Known brain metastases at screening.
• Life expectancy of less than three months.
• Patients with TNM classification M1c at screening.
• Prior systemic anti-cancer treatment within four weeks of screening.
• Prior treatment with systemic corticosteroids or other immunosuppressants within four weeks of screening.
• Previous (within five years) or current malignancy at other sites with the exception of curatively treated local tumours such as carcinoma-in-situ of the cervix, basal or squamous cell carcinoma of the skin.
• Pregnant or lactating women.
• Presence of any uncontrolled and significant medical or psychiatric condition which would interfere with trial safety assessments. Caution should be used for patients with suspected or diagnosed epilepsy.
• Any electronic stimulation device such as cardiac demand pacemaker, automatic implantable cardiac defibrillator, nerve stimulators or deep brain stimulators.
• Individuals in which a skin-fold measurement of the cutaneous and subcutaneous tissue for all eligible injection sites (deltoid or quadriceps muscles with intact lymph drainage) exceeds 40 mm.
• Individuals with a heart rate of ≤ 50 beats per minute, history of significant cardiac abnormality and/or significant abnormal baseline electrocardiogram (ECG) readout.
• Treatment with any investigational product within the four weeks preceding screening.

Contacts and Locations

Locations

United Kingdom

Department of Medical Oncology, The Royal Surrey County Hospital

Guildford, Surrey, United Kingdom, GU2 7XX

St James' Institute of Oncology

Leeds, United Kingdom, LS9 7TF

Christie Hospital

Manchester, United Kingdom, M20 4BX

Department of Clinical Oncology, City Hospital

Nottingham, United Kingdom, NG5 1PB

Department of Medical Oncology, Southampton General Hospital

Southampton, United Kingdom, SO16 6YD

Sponsors and Collaborators

Scancell Ltd

Investigators

• Study Director: Poulam M Patel, MD; Department of Clinical Oncology, City Hospital, Nottingham, UK
• Principal Investigator: Paul Lorigan, MD; Department of Medical Oncology, Christie Hospital, Manchester, UK
• Principal Investigator: Maria Marples, MD; St James' Institute of Oncology, Leeds, UK
• Principal Investigator: Christian Ottensmeier, MD; Department of Medical Oncology, Southampton General Hospital, UK
• Principal Investigator: Hardev Pandha, MD; Department of Medical Oncology, Royal Surrey County Hospital, Guildford, UK

More Information

• Responsible Party: Scancell Ltd
• ClinicalTrials.gov Identifier: NCT01138410 History of Changes
• Other Study ID Numbers: SCIB1-001
• First Posted: June 7, 2010
• Last Update Posted: August 21, 2017
• Last Verified: August 2017

Keywords provided by Scancell Ltd:

Immunotherapy; Melanoma; Gene therapy; DNA plasmid; Cancer vaccine; Electroporation; CTL response

Additional relevant MeSH terms:

Melanoma; Neuroendocrine Tumors; Neuroectodermal Tumors; Neoplasms, Germ Cell and Embryonal; Neoplasms by Histologic Type; Neoplasms; Neoplasms, Nerve Tissue; Nevi and Melanomas; Immunologic Factors; Physiological Effects of Drugs